非霍奇金淋巴瘤患者接受B细胞清除免疫治疗后Covid-19住院时间延长且死亡率更高
该研究纳入2020年3-4月法国16家医院收治的111例淋巴瘤合并Covid-19成年患者,分析住院时间延长(以死亡为竞争风险)的决定因素与结局。中位住院时间14天,6个月总生存率69%。近期接受抗CD20治疗与住院时间延长(SHR 2.26)和死亡风险升高(HR 2.17)独立相关,年龄≥70岁和复发/难治淋巴瘤亦为危险因素。
要点
- 近期接受抗CD20治疗与Covid-19住院时间延长和死亡风险升高独立相关。
- 年龄≥70岁和复发/难治淋巴瘤也是住院时间延长和总生存下降的危险因素。
- 淋巴瘤合并Covid-19患者6个月总生存率为69%,中位住院时间14天。
核心结论
- 年龄≥70岁、复发/难治淋巴瘤和近期接受抗CD20治疗是淋巴瘤患者因Covid-19住院时住院时间延长和死亡的危险因素。
研究设计与样本
- 研究纳入2020年3月和4月法国16家医院收治的111例因Covid-19住院的成年淋巴瘤患者。
- 住院时间延长以死亡为竞争风险进行分析。
主要发现
- 住院前12个月内79例(71%)接受淋巴瘤治疗,其中63例(57%)接受抗CD20治疗,14例(12%)为复发/难治疾病。
- 中位住院时间14天(范围1-235),中位随访191天(范围3-260)时6个月总生存率为69%。
- 多变量分析中,近期接受抗CD20治疗与住院时间延长相关(SHR 2.26,95%CI 1.42-3.6,p<0.001)。
- 近期接受抗CD20治疗与死亡风险升高相关(HR 2.17,95%CI 1.04-4.52,p=0.039)。
临床怎么用
- 对于近期接受抗CD20治疗的淋巴瘤患者,应警惕Covid-19住院时间延长和死亡风险升高。
- 年龄≥70岁或复发/难治淋巴瘤患者因Covid-19住院时需加强风险评估与管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prolonged Covid-19 is an emerging issue for patients with lymphoma or immune deficiency. We aimed to examine prolonged length of in-hospital stay (LOS) due to Covid-19 among patients with lymphoma and assess its determinants and outcomes. Adult patients with lymphoma admitted for Covid-19 to 16 French hospitals in March and April, 2020 were included. Length of in-hospital stay was analyzed as a competitor vs death. The study included 111 patients. The median age was 65 years (range, 19-92). Ninety-four patients (85%) had B-cell non-Hodgkin lymphoma. Within the 12 months prior to hospitalization for Covid-19, 79 patients (71%) were treated for their lymphoma. Among them, 63 (57%) received an anti-CD20 therapy. Fourteen patients (12%) had relapsed/refractory disease. The median LOS was 14 days (range, 1-235). After a median follow-up of 191 days (3-260), the 6-month overall survival was 69%. In multivariable analyses, recent administration of anti-CD20 therapy was associated with prolonged LOS (subdistribution hazard ratio 2.26, 95% confidence interval 1.42-3.6, p < 0.001) and higher risk of death (hazard ratio 2.17, 95% confidence interval 1.04-4.52, p = 0.039). An age ≥ 70 years and relapsed/refractory lymphoma were also associated with prolonged LOS and decreased overall survival. In conclusion, an age ≥ 70 years, a relapsed/refractory lymphoma and recent administration of anti-CD20 therapy are risk factors for prolonged LOS and death for lymphoma patients hospitalized for Covid-19. These findings may contribute to guide the management of lymphoma during the pandemic, support evaluating specific therapeutic approaches, and raise questions on the efficacy and timing of vaccination of this particular population.
引用
- Duléry R, Lamure S, Delord M, et al. Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am J Hematol. 2021. PMID: 33909916. doi:10.1002/ajh.26209
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。